Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Liver Diseases

  Free Subscription


22.06.2026

1 Am J Gastroenterol
2 Biochem Biophys Res Commun
6 BMC Cancer
6 BMC Gastroenterol
1 Br J Surg
1 Cancer Res
1 Dig Dis Sci
2 Endoscopy
1 Eur J Pediatr
12 Hepatology
2 Indian J Gastroenterol
10 J Hepatol
2 J Pediatr
1 Oncogene
1 PLoS One
1 Proc Natl Acad Sci U S A
1 Radiol Artif Intell
1 Transplant Proc
3 Transplantation


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Gastroenterol

  1. PARK J, Tran S, Ogawa E, Huang CF, et al
    Higher incidence of hepatocellular carcinoma in suppressed hepatitis B cirrhosis compared to cured hepatitis C cirrhosis.
    Am J Gastroenterol. 2026 Jun 9. doi: 10.14309/ajg.0000000000004071.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  2. SAEED HY, Orabi SH, Mansour DA, Korany RMS, et al
    Ameliorating effects of Coenzyme Q10 and its nanosuspension against cyclophosphamide-induced hepatoxicity in rats.
    Biochem Biophys Res Commun. 2026;828:154137.
    PubMed         Abstract available

  3. ZHANG H, Liu X, Liu Y, Gong D, et al
    Identification of PANoptosis-related gene SIK1 in MASLD by bioinformatics, machine learning and experimental validation.
    Biochem Biophys Res Commun. 2026;827:154019.
    PubMed         Abstract available


    BMC Cancer

  4. KARUNAKARA SH, Ramaswamy G, Kabekkodu SP, Prashant A, et al
    Methylation-mediated regulation of tumor-suppressor function of the miR-379/656 (C14MC) cluster and its clinical utility in hepatocellular carcinoma.
    BMC Cancer. 2026 Jun 12. doi: 10.1186/s12885-026-16318.
    PubMed         Abstract available

  5. SHI H, Zhang P, Wei Q, He H, et al
    Bioinformatics mining and clinical validation of CD274 as a prognostic indicator in hepatocellular carcinoma.
    BMC Cancer. 2026 Jun 15. doi: 10.1186/s12885-026-16329.
    PubMed         Abstract available

  6. HUANG W, Ding J, Yuan H, Li Z, et al
    MRI radiomics and (90)Y PET dosimetry for predicting hepatocellular carcinoma response after radioembolization.
    BMC Cancer. 2026 Jun 16. doi: 10.1186/s12885-026-16345.
    PubMed         Abstract available

  7. REN J, Xu S, He X, Ye H, et al
    Correlated expression of MYBL2 and CCL5 defines an immunosuppressive microenvironment and predicts poor prognosis in intrahepatic cholangiocarcinoma.
    BMC Cancer. 2026 Jun 17. doi: 10.1186/s12885-026-16219.
    PubMed         Abstract available

  8. ALFAWAZ MS, Elmorsy EM, Al Doghaither HA, Al-Ghafari AB, et al
    Hepatorenal protective and antitumor effects of astaxanthin-loaded chitosan nanoparticles against ehrlich ascites carcinoma in mice through antioxidant, anti-inflammatory, and apoptotic pathway modulation.
    BMC Cancer. 2026 Jun 17. doi: 10.1186/s12885-026-16275.
    PubMed         Abstract available

  9. WEI F, Liu W, Chen Z, Chen Z, et al
    FGFR4-high expression is associated with an immune-responsive phenotype in HCC and predicts inferior efficacy of lenvatinib plus PD-1 blockade.
    BMC Cancer. 2026;26:759.
    PubMed         Abstract available


    BMC Gastroenterol

  10. REN X, Liu Z, Wang Y, Guo P, et al
    Integrative multi-omics analysis reveals a gut-liver axis signature of metabolic reprogramming associated with response to transarterial chemoembolization in hepatocellular carcinoma.
    BMC Gastroenterol. 2026 Jun 17. doi: 10.1186/s12876-026-04978.
    PubMed         Abstract available

  11. MARINESCU A, Olita M, Moroianu A, Vasilescu A, et al
    Validation of recipient-specific kinetic prediction scores for allograft failure after liver transplantation: a single centre retrospective analysis.
    BMC Gastroenterol. 2026;26:354.
    PubMed         Abstract available

  12. LI B, Zhang Y, Li Z, Chen Z, et al
    A novel serum metabolite classifier for identifying Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) integrating metabolomics and machine learning.
    BMC Gastroenterol. 2026;26:361.
    PubMed         Abstract available

  13. DE SOUZA NS, Cotrim HP, de Andrade ARCF
    Moderate alcohol consumption and clinical outcomes in MASLD: a systematic review and meta-analysis of longitudinal cohorts.
    BMC Gastroenterol. 2026;26:368.
    PubMed         Abstract available

  14. HE C, Liu P, Liu X, Cai P, et al
    Changing etiological spectrum of cirrhosis in China: a systematic review and meta-analysis.
    BMC Gastroenterol. 2026 Jun 12. doi: 10.1186/s12876-026-05009.
    PubMed         Abstract available

  15. LIU J, Liu X, Wang M, Wei S, et al
    Hypotension among patients with liver failure treated by artificial liver support system: risk factors and coping strategies.
    BMC Gastroenterol. 2026;26:376.
    PubMed         Abstract available


    Br J Surg

  16. YUZA K, Chatzipanagiotou OP, Hobeika C, Aucejo F, et al
    Metastatic Lymph Node Burden and Invasive Tumour Features Inform First Recurrence Patterns After Curative-Intent Resection for Intrahepatic Cholangiocarcinoma.
    Br J Surg. 2026 Jun 16:znag074. doi: 10.1093.
    PubMed         Abstract available


    Cancer Res

  17. ZENG Y, Huang Z, Qiu J, Yuan G, et al
    HSPA6 Confers Lenvatinib Resistance in Hepatocellular Carcinoma by Promoting Phase Separation-Mediated TXNRD1 Stabilization to Suppress Ferroptosis.
    Cancer Res. 2026 Jun 18. doi: 10.1158/0008-5472.CAN-26-0314.
    PubMed         Abstract available


    Dig Dis Sci

  18. KHALIL SM, Al-Sharif L, Diaz I, Souza M, et al
    Incidence of Cirrhosis in Fibrotic Metabolic Dysfunction-Associated Steatohepatitis: A Meta-Analysis of Placebo Arms from Randomized Clinical Trials.
    Dig Dis Sci. 2026 Jun 18. doi: 10.1007/s10620-026-10057.
    PubMed         Abstract available


    Endoscopy

  19. QIU X, Lin X, Li Y, Zhong Z, et al
    Utilizing the novel peroral choledochoscope for the treatment of hepatolithiasis about primary sclerosing cholangitis.
    Endoscopy. 2026 Jun 12. doi: 10.1055/a-2885-8233.
    PubMed        

  20. MIWA H, Tsunoda S, Matsuoka Y, Oishi R, et al
    Antegrade partial stent-in-stent deployment through dual endosonographically-created routes for recurrent bile duct cancer after right hepatectomy with hepaticojejunostomy.
    Endoscopy. 2026 Jun 12. doi: 10.1055/a-2884-1560.
    PubMed        


    Eur J Pediatr

  21. WARLOP J, Borloo N, Muniraman H, Michniewicz B, et al
    Time-dependent pattern of liver injury biomarkers in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.
    Eur J Pediatr. 2026;185:501.
    PubMed         Abstract available


    Hepatology

  22. FORTUNY M, Chan LL, da Fonseca LG, Abou-Alfa GK, et al
    Beyond second-line therapy: Strategic sequencing of systemic treatments in advanced hepatocellular carcinoma.
    Hepatology. 2026 Jun 8. doi: 10.1097/HEP.0000000000001767.
    PubMed         Abstract available

  23. SIDHU G
    Bile acids as the silent harbinger: Early signals of portal hypertension after "successful" Kasai.
    Hepatology. 2026;84:1-2.
    PubMed        

  24. PATEL KS, Arab JP
    Good vibrations: Using VCTE to predict hepatic decompensation in MASLD.
    Hepatology. 2026;84:7-8.
    PubMed        

  25. REID MV, Fredickson G, Mashek DG
    Mechanisms coupling lipid droplets to MASLD pathophysiology.
    Hepatology. 2026;84:273-291.
    PubMed         Abstract available

  26. SIMON-CODINA B, Cacho-Pujol J, Moles A, Melgar-Lesmes P, et al
    Reprogramming macrophages to treat liver diseases.
    Hepatology. 2026;84:251-272.
    PubMed         Abstract available

  27. SUZUKI H, Fujiwara N, Singal AG, Baumert TF, et al
    Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic.
    Hepatology. 2026;84:292-320.
    PubMed         Abstract available

  28. TANG L, Hou Y, Di T, Lu X, et al
    Anti-angiogenic therapy combined with immune checkpoint blockade mediates CCR7 + CD8 + T-cell entry into HCC through high endothelial venules.
    Hepatology. 2026;84:57-73.
    PubMed         Abstract available

  29. TANAKA T, Shane DM, Lai JC
    Sex and body size disparities under MELD 3.0: Evaluation of persisting gaps in liver transplant access.
    Hepatology. 2025 Oct 16. doi: 10.1097/HEP.0000000000001581.
    PubMed         Abstract available

  30. YOUNOSSI ZM, de Avila L, Petta S, Hagstrom H, et al
    Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study.
    Hepatology. 2026;84:161-174.
    PubMed         Abstract available

  31. LAM TBN, Yates KP, Noon SL, Newton KP, et al
    Reclassifying pediatric NAFLD using the steatotic liver disease framework: A multicenter retrospective study from the NASH CRN.
    Hepatology. 2026;84:129-142.
    PubMed         Abstract available

  32. YOUNOSSI ZM, de Avila L, Petta S, Hagstrom H, et al
    Predictors of fibrosis, clinical events, and mortality in MASLD: Data from the Global-MASLD study.
    Hepatology. 2026;84:204-215.
    PubMed         Abstract available

  33. ZHANG Y, Lee HW, Lin H, Tsochatzis E, et al
    Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver disease.
    Hepatology. 2026;84:175-190.
    PubMed         Abstract available


    Indian J Gastroenterol

  34. V ANTONY A, Pillai MT, Das R, Rajan R, et al
    Change in liver fat content in patients following pancreatic resections.
    Indian J Gastroenterol. 2026;45:756-763.
    PubMed         Abstract available

  35. EID RA, Attia D, Soliman AS, Abd Elmaogod EA, et al
    Impact of sleeve gastrectomy on the course of metabolic associated fatty liver disease.
    Indian J Gastroenterol. 2026;45:745-755.
    PubMed         Abstract available


    J Hepatol

  36. YU S, Yu J, Zhang W, Cheng L, et al
    Retraction notice to "Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation" [J Hepatol 61 (2014) 809-815].
    J Hepatol. 2026 Jun 12:S0168-8278(26)02588-2. doi: 10.1016/j.jhep.2026.
    PubMed        

  37. LOMBARDI P, Ramon-Gil E, Raja RQ, Brunetti L, et al
    A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma.
    J Hepatol. 2026 Jun 15:S0168-8278(26)02605-X. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available

  38. LI J, Luo B, Zhang N, Gao A, et al
    Triple Parallel TIPSs for Porto-sinusoidal Vascular Disorder with Refractory Hemorrhage: Portal Hypertension, But Not as We Know It.
    J Hepatol. 2026 Jun 16:S0168-8278(26)02635-8. doi: 10.1016/j.jhep.2026.
    PubMed        

  39. DENG Z, Xiao G, Han Y, Ren H, et al
    The cWHV Model Preferentially Recapitulates Intrahepatic CD8 T-Cell Programs of the Immune-Active Phase of HBV Infection.
    J Hepatol. 2026 Jun 17:S0168-8278(26)02639-5. doi: 10.1016/j.jhep.2026.
    PubMed        

  40. MA X, Wang X, Tian H, Huang Y, et al
    Hepatic-IL-22RA1 is indispensable for IL-22-induced in vitro expansion of primary mouse hepatocytes.
    J Hepatol. 2026 Jun 18:S0168-8278(26)02641-3. doi: 10.1016/j.jhep.2026.
    PubMed        

  41. DUKEWICH M, Wilson LA, Dodge JL, Yuan L, et al
    Longitudinal changes in cardiometabolic risk factors are associated with changes in liver stiffness in adults with MASLD.
    J Hepatol. 2026;85:37-47.
    PubMed         Abstract available

  42. SATTAR N, Dalakoti M, Alazawi W, Aroda VR, et al
    Cardiovascular risk in MASLD: What multiple lines of evidence reveal.
    J Hepatol. 2026;85:159-164.
    PubMed         Abstract available

  43. ENGELMANN C, Verma N, Qi T, Kerbert AJC, et al
    Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohorts.
    J Hepatol. 2026;85:91-105.
    PubMed         Abstract available

  44. MULLER L, Kather JN, Marquardt JU, Reig M, et al
    BCLC classification and AI-based image quantification: What is meant to be will come together - but how and when?
    J Hepatol. 2026;85:165-173.
    PubMed         Abstract available

  45. WU P, Wang Y, Cohen JC, Hobbs HH, et al
    Tissue-specific regulation of PNPLA3 promotes lipid remodeling in response to dietary and environmental challenges.
    J Hepatol. 2026;85:48-60.
    PubMed         Abstract available


    J Pediatr

  46. KELLY M, Ali S, Huerta A, Hsu EK, et al
    Characterizing Barriers to Living Donor Liver Transplantation for Pediatric Recipients: Qualitative Results from the SOCIAL-Tx Study.
    J Pediatr. 2026 Apr 21:115112. doi: 10.1016/j.jpeds.2026.115112.
    PubMed         Abstract available

  47. HOSKINS BJ, Mogul DB, Chen C, Karnsakul W, et al
    Maralixibat Improves Xanthomas and Hypercholesterolemia in Children with Alagille Syndrome: A Post Hoc Integrated Analysis From Two Clinical Trials.
    J Pediatr. 2026;294:115108.
    PubMed         Abstract available


    Oncogene

  48. ZHANG C, Chen X, Yao H, Chen Y, et al
    STK39 promotes the evolution cascade of hepatocellular carcinoma by facilitating PKR/NF-kappaB-mediated macrophage inflammatory response.
    Oncogene. 2026 Jun 13. doi: 10.1038/s41388-026-03859.
    PubMed         Abstract available


    PLoS One

  49. WANG R, Liao Q, Liu X, Sun L, et al
    Analysis of molecular targets and mechanisms of Bisphenol F (BPF)-induced non-alcoholic fatty liver disease (NAFLD) based on network toxicology and molecular dynamics.
    PLoS One. 2026;21:e0351730.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  50. SU Q, Yang Y, Ren J, Zhang Y, et al
    RNF126 is a peroxisomal fate switch enabling redifferentiation therapy in hepatocellular carcinoma.
    Proc Natl Acad Sci U S A. 2026;123:e2535777123.
    PubMed         Abstract available


    Radiol Artif Intell

  51. MATHAI TS, Balamuralikrishna PTS, Batheja V, Wang X, et al
    Automated Delineation of Couinaud Segments on CT for Future Liver Remnant Volumetry.
    Radiol Artif Intell. 2026 May 6:e250808. doi: 10.1148/ryai.250808.
    PubMed         Abstract available


    Transplant Proc

  52. SHARMA A, Usman L, Lai JC, Jutras G, et al
    Association of Frailty With Waitlist and Post-Transplant Outcomes in Patients With Hepatopulmonary Syndrome and Portopulmonary Hypertension.
    Transplant Proc. 2026 Jun 18:S0041-1345(26)00268.
    PubMed         Abstract available


    Transplantation

  53. TANG NSY, Teng MLP, Selvakumar A, Ng CWH, et al
    Delisting From Clinical Improvement in Liver Cirrhosis: A Machine Learning Decision Tree Analysis.
    Transplantation. 2026;110:e1447-e1455.
    PubMed         Abstract available

  54. AMARA D, Melehy A, Feng J, Rodgers A, et al
    Automated Computed Tomography-based Liver Steatosis Risk Stratification of Deceased Organ Donors Using Real-world Data.
    Transplantation. 2026;110:e1475-e1484.
    PubMed         Abstract available

  55. MAROTO-SERRAT C, Marin-Blazquez M, Sanus F, Caballeria-Casals A, et al
    Visceral Adipose Tissue and its Crosstalk With the Liver Allograft: Implications for Transplant Outcomes.
    Transplantation. 2026;110:e1391-e1401.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum